FDA's Top Q4 Blockbuster Drug Decisions
FDA's Top Q4 Blockbuster Drug Decisions
Fierce Biotech
Linjeta
Biodel
Afrezza
MannKind
FDA
Benlysta
Human Genome
GSK
Bydureon
Eli Lilly
Amylin
Alkermes
Brilinta
AstraZeneca
Pradaxa
Boehringer Ingelheim
Qnexa
Vivus
Contrave
Orexigen
ipilimumab
Bristol-Myers Squibb
Merck KGaA
cladribine
New Pfizer drug may add to mix in lung cancer war
New Pfizer drug may add to mix in lung cancer war
Reuters
lung cancer
Pfizer
Halozyme cutting 25 percent of its work force
Halozyme cutting 25 percent of its work force
Yahoo/AP
layoffs
Halozyme
For Dendreon’s Provenge, a New Competitor Looms
For Dendreon’s Provenge, a New Competitor Looms
WSJ Online
Dendreon
Provenge
prostate cancer
abiraterone
JNJ
Big Pharma, Soros in emerging-markets deals
Big Pharma, Soros in emerging-markets deals
Fierce Pharma
Sihuan
China
George Soros
India
Paras
10 Pharmaceutical Stocks With Up to 88% Upside
10 Pharmaceutical Stocks With Up to 88% Upside
TheStreet.com
Novartis
Allergan
Shire
AstraZeneca
Abbott Laboratories
Merck
Pfizer
Teva Pharmaceuticals
Warner Chilcott
Valeant Pharmaceuticals
Pfizer buyout offer sends King shares up 39%
Pfizer buyout offer sends King shares up 39%
Marketwatch
Pfizer
King
M&A
Plavix May Get A Boost From A Curious Study
Plavix May Get A Boost From A Curious Study
Pharmalot
Plavix
Sanofi
Bristol-Myers Squibb
Novartis Paid Doc Who Urged Use of Seizure Meds on Bipolar Kids
Novartis Paid Doc Who Urged Use of Seizure Meds on Bipolar Kids
BNET Pharma
physicial payments
Novartis
bipolar disorder Trileptal
TAP deal with Novartis brings ImmunoGen US$45 million upfront
TAP deal with Novartis brings ImmunoGen US$45 million upfront
Pharma Times, UK
TAP
Novartis
Immunogen

Pages